

In re Application of:

NEEF et al.

Serial No.: 10/031,198

Group Art Unit: 1288

Filed :July 2, 2002

Examiner: Unassigned

For: NOVEL C-19-HALOGEN-SUBSTITUTED STEROIDS OF THE ANDROST-9(11)-ENE-SERIES, METHODS FOR THE PRODUCTION AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

CITI	ED MATERIALS
Appl	licant(s) hereby disclose the information listed in the attached form PTO-1449.
	Copies of materials listed but not attached were cited in parent application Seria No; see 37 C.F.R. § 1.98(d).
⊠	Copies of materials listed but not attached were cited in an International Search Report dated <u>April 18, 2002</u> ; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTC in the Notice of Acceptance mailed <u>August 12, 2002</u> .
ADI	DITIONAL INFORMATION
LAN	IGUAGE
	All listed materials are in the English language; see 37 C.F.R. § 1.98.

	*	
All listed materials are in the English language; see 37 C.F.R. § 1.98.		
Non-English language reference	ces:	
☐ The reference(s): commercial data bases to corre		indicated by spectively.
☐ (An) English-language provided.	translation(s) of the references:	is (are)
☐ A commercial English-provided.	-language abstract of reference(s)	is (are)

An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

<u>FEES</u>

Z)	140 fee is required for this information Disclosure Statement because.
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
	This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
	☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i)
	A fee is required for this Information Disclosure Statement:
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
	This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.
CERT	<u>IFICATION</u>
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$\frac{\\$}{200}\$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Jennifer V. Brangan Reg. No. 40,924

Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1867

Date: October 11, 2002

JJB/cas

K:\Sch\1867\Information Disclosure Statement.doc